IDO Inhibitor and Checkpoint Antibody Combination Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatment methods, particularly those involving checkpoint inhibitors, face limitations in extending benefits to more patients due to immune evasion mechanisms like IDO-mediated immunosuppression, necessitating new approaches to enhance T cell activation and tumor infiltration.
Innovation Solution
Administering a combination of a monoclonal antibody, such as nivolumab, with the compound (R)-N-(4-chlorophenyl)-2-(cis-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide or its salt, at doses ranging from 100 mg to 200 mg daily, to inhibit IDO activity and enhance immune response against cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If checkpoint inhibitors are used to treat cancer, then T cell activation is enhanced, but immune evasion mechanisms like IDO-mediated immunosuppression limit the effectiveness
Solution Approach 1:
The treatment approach is segmented into two distinct components: checkpoint inhibitors (anti-PD-1 or anti-CTLA-4 antibodies) that enhance T cell activation, and IDO inhibitors (compound of Formula I) that block the immunosuppressive pathway. This segmentation allows each component to target a specific mechanism of immune evasion independently, thereby overcoming the limitations of using checkpoint inhibitors alone.
Solution Approach 2:
The patent combines checkpoint inhibitors and IDO inhibitors into a dual therapy regimen. This merging of two different therapeutic mechanisms creates a synergistic effect where the checkpoint inhibitor enhances T cell activation while the IDO inhibitor prevents the tumor from suppressing the immune response through kynurenine production, thereby overcoming immune evasion more effectively than either agent alone.
2Reliability
If higher doses of IDO inhibitor are administered to maximize immune response, then kynurenine levels decrease, but safety and tolerability may be compromised
Solution Approach 1:
The patent optimizes the dosage parameters of the IDO inhibitor (compound of Formula I) to achieve effective kynurenine suppression while maintaining safety. Clinical trials evaluated doses of 100 mg and 200 mg daily, identifying the optimal dose range that maximizes immune response enhancement without causing unacceptable adverse effects. This parameter optimization allows the treatment to achieve therapeutic efficacy while maintaining tolerability.
3Reliability
If combination therapy is used to overcome immune evasion, then antitumor efficacy increases, but treatment complexity increases
Solution Approach 1:
The patent merges checkpoint inhibitors and IDO inhibitors into a unified combination therapy regimen. This merging approach addresses multiple immune evasion mechanisms simultaneously, thereby enhancing antitumor efficacy. The treatment protocol integrates both agents with defined dosing schedules, making the complex regimen manageable through standardized administration protocols.
Solution Approach 2:
The combination therapy regimen is designed to be universally applicable across multiple cancer types that exhibit IDO-mediated immunosuppression. The dual mechanism of action (checkpoint inhibition plus IDO inhibition) provides multi-functionality in overcoming various immune evasion strategies employed by different tumors, making the treatment broadly effective while maintaining a consistent administration approach.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This combination therapy effectively reduces intratumoral kynurenine levels, increases CD8+ T cell proliferation, and demonstrates preliminary antitumor efficacy with tolerable safety profiles, as shown in clinical trials for advanced cancers like bladder and cervical cancers.
Implementation Method 1
IDO allows tumor escape through kynurenine production... suppression of tryptophan degradation by inhibition of IDO activity
Implementation Method 2
Checkpoint inhibitors have transformed cancer care... enhance T cell activation when the T cells are suppressed by pregnancy, malignancy, or a virus
Data Source
AI summary
The disclosure is directed to methods of treating cancer in subjects with a combination of a monoclonal antibody and (R)-N-(4-chlorophenyl)-2-(cis-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide, or a salt thereof.